Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04819373 · ClinicalTrials.gov registry record · Phase 2
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
A Phase 2 study, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04819373 is a Phase 2 study that has completed, run by Eikon Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT04819373, a Phase 2 study, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
Interventions
- DRUG BDB001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04819373
The ClinicalTrials.gov registry entry for NCT04819373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BDB001 is the first listed.
NCT04819373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04819373 about?
NCT04819373 is a clinical study titled "BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors". BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
What is the current status of trial NCT04819373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-08-30. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT04819373?
The interventions under investigation include: BDB001 (DRUG).
Who is sponsoring clinical trial NCT04819373?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.